Syntara Ltd

SNT

Company Profile

  • Business description

    Syntara Ltd is a clinical-stage drug development company working to bring new and life-changing treatments to patients in need. It is targeting extracellular matrix dysfunction with its expertise in amine oxidase chemistry and other technologies to develop novel medicines for blood cancers and conditions linked to inflammation and fibrosis. The company has various drug candidates in its pipeline such as SNT-5505, SNT-4728, SNT-5382, and SNT-8370 as a potential treatment for cancer, skin scarring, and neuroinflammation.

  • Contact

    20 Rodborough Road
    Unit 2
    Frenchs Forest
    SydneyNSW2086
    AUS

    T: +61 287601480

    E: david.mcgarvey@pharmaxis.com.au

    https://www.syntaratx.com.au

  • Sector

    Healthcare

    Stock type

    Defensive

  • Industry

    Drug Manufacturers - Specialty & Generic

    Fiscal Year End

    30 June 2025

    Employees

    93

Syntara Ltd News & Analysis

stocks

CSL remains favourite, but biotech field broadening

The biotech giant has jumped 22pc a year for the past decade but new players are emerging.

Morningstar Investment Ideas

Markets

Index
Last price
Change
% Change
All Ordinaries8,529.5038.000.45%
CAC 407,602.0624.170.32%
DAX 4019,508.29134.460.69%
Dow JONES (US)43,014.62150.760.35%
FTSE 1008,292.6639.010.47%
HKSE21,092.87159.11-0.75%
NASDAQ18,504.83161.890.88%
Nikkei 22539,605.80224.910.57%
NZX 50 Index12,766.7578.89-0.61%
S&P 5005,856.7241.690.72%
S&P/ASX 2008,252.8038.300.47%
SSE Composite Index3,284.3266.582.07%

Market Movers